Similar Papers

Paper Title
Journal
Date
Author
Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism.
Mizuki Kobayashi ... Chikara Ohyama
Genes | VOL. 13
Mizuki Kobayashi, et. al.Mizuki Kobayashi ... Chikara Ohyama
05 Jul 2022
Abstract 6670: Association between circulating CD4 memory T cell levels and severe immune-related adverse events in melanoma patients treated with immune checkpoint blockade
Abul Usmani ... Peter K Harris
Cancer Research | VOL. 83
Abul Usmani, et. al.Abul Usmani ... Peter K Harris
04 Apr 2023
Correlation of insulin-receptor expression with efficacy of axitinib in patients with advanced renal cell carcinoma.
Masayuki Takahashi ... Yoshito Kusuhara
Journal of Clinical Oncology | VOL. 35
Masayuki Takahashi, et. al.Masayuki Takahashi ... Yoshito Kusuhara
20 Feb 2017
Efficacy and safety of first-line nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma: A multicenter retrospective study.
Toshikazu Tanaka ... Hiroyuki Ito
International journal of urology : official journal of the Japanese Urological Association | VOL. 27
Toshikazu Tanaka, et. al.Toshikazu Tanaka ... Hiroyuki Ito
06 Sep 2020
View more papers

More From: European Urology

Paper Title
Journal
Date
Author
Editorial Board
-
European Urology | VOL. 87
--
01 Feb 2025
Platinum Hall of Fame
-
European Urology | VOL. 87
--
01 Feb 2025
Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitors and Subsequent Therapy for Renal Cell Carcinoma.
Jens Bedke ... Axel Bex
European urology | VOL. -
Jens Bedke, et. al.Jens Bedke ... Axel Bex
01 Feb 2025
Re: Characterizing Psychological Resources and Resilience in Patients with Bladder Cancer: Associations with Frailty and Quality of Life.
Rodolfo Hurle ... Massimo Lazzeri
European urology | VOL. -
Rodolfo Hurle, et. al.Rodolfo Hurle ... Massimo Lazzeri
01 Feb 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.